Skip to main content

Table 1 Intermediate- and high-risk prostate cancer patient’s and treatment characteristics

From: The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy

Number of patients

103

Age (years)

 

 Median

69.1

 Range

56.0 – 81.0

T stage

 

 T1

27 (26.2%)

 T2

24 (23.3%)

 T3

51 (49.5%)

 T4

1 (1.0%)

Gleason score

 

 <7

60 (58.2%)

 7

40 (38.8%)

 >7

2 (2.0%)

 Unknown

1 (1.0%)

PSA (ng/mL)

 

 Median

13.1

 Range

3.1 – 20.0

Risk category

 

 Intermediate-risk

53 (51.5%)

 High-risk

50 (48.5%)

Dose (Gy)

 

 Median

74.0

 Range

64.4 – 78.4

ADT

 

 Yes

57 (55.3%)

 No

46 (44.7%)

  1. PSA prostatic-specific antigen ; ADT anti-androgen deprivation therapy.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us